title: [Clinicopathological features of Luminal B-like breast cancer].
abstract: OBJECTIVE
  To explored the clinicopathological features of Luminal B-like breast cancer and analyze the value of St. Gallen consensus in its treatment.
  
  
  METHODS
  The patients with invasive breast cancer treated at our hospital between January 2010 and December 2012 were recruited and divided into five subtypes according to the criteria of St. Gallen International Expert Consensus report 2013. And their TNM stages, pathological characteristics and Ki-67 status were analyzed for Luminal B-like subtype.
  
  
  RESULTS
  The Luminal B-like subtype was found in 390 patients (52.8%), human epidermalgrowth factor receptor 2(HER-2) positive in 89 patients (22.8%) and negative in 301 patients (77.2%).Only 7.3% required chemotherapy based upon the result of gene detection.
  
  
  CONCLUSIONS
  Only those patients for whom the need of chemotherapy is to be determined shall really benefit from gene detection.
authors: Breast Disease Center, Peking University Shenzhen Hospital, Shenzhen 518036, China.
authors: Hui
authors: H
authors: Hu
authors: Qian
authors: Q
authors: Liu
authors: Ling
authors: L
authors: Xu
authors: Jingming
authors: J
authors: Ye
authors: Xuening
authors: X
authors: Duan
authors: Peking University First Hospital, Beijing 100034, China. Email: Liuyinhua@medmail.com.cn.
authors: Yinhua
authors: Y
authors: Liu
mesh_terms: D001943:Breast Neoplasms; D006801:Humans; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D018719:Erb-b2 Receptor Tyrosine Kinases
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases